4 results about "Ivermectin" patented technology

The application relates to the technical field of fine chemical production, and particularly discloses a crystallization process of short-rod-shaped ivermectin, which comprises the following steps: dissolving ivermectin crude product in a crystallization solvent, heating to 50-55 DEG C, adding a crystallization agent, uniformly mixing, then cooling to 35-40 DEG C at a rate of 0.1-0.3 DEG C / min, adding ivermectin crystal seeds, continuously cooling to 5-15 DEG C, and incubating and crystallizing to obtain ivermectin products. The crystallization process of ivermectin provided by the application realizes effective control of the particle size and crystal habit of ivermectin products in the crystallization process by adopting a combination strategy of selecting a specific crystallization solvent, adding a crystallization agent and crystal seeds at specific stages, controlling the cooling rate and the incubation time, obtaining short-rod-shaped ivermectin products with uniform particle size distribution, and the products have good fluidity, are convenient for subsequent preparation application, do not need repeated crystallization for multiple times, effectively reduce the cost of the crystallization process, and have extremely high practical application value.

This invention relates to the field of veterinary drug technology, and proposes a compound composition for the prevention and treatment of shrimp hepatocellular carcinoma and its preparation method. The compound composition comprises the following raw materials: albendazole, ivermectin, and glycyrrhizic acid monoammonium salt. The components in the compound composition for the prevention and treatment of shrimp hepatocellular carcinoma provided by this invention work synergistically to safely control the disease and ensure the healthy and sustainable development of aquaculture.

Laboratory apparatus for evaluation and modulation of ivermectin drug–induced neurotoxicity using therapeutic intervention agents

The application belongs to the technical field of antibiotic application, and discloses that microplastics affect the absorption of ciprofloxacin in the intestinal tract through the TLR4 / NF-kappa B pathway regulating P-gp protein. Our research finds that microplastics can activate the expression of P-gp glycoprotein in intestinal epithelial cells through the NF-kappa B pathway in the intestinal tract, thereby reducing the absorption of ciprofloxacin hydrochloride in the intestinal tract, and further affecting the core mechanism of pharmacokinetics and pharmacodynamics of ciprofloxacin hydrochloride in animals. Pyruvate ethyl effectively inhibits the NF-kappa B pathway. The application also finds that after ivermectin inhibits the P-gp glycoprotein of Caco2 cells, the P-gp glycoprotein cannot efflux ciprofloxacin hydrochloride, so that the content of ciprofloxacin hydrochloride in Caco2 cells increases. Therefore, the application also protects the application of ivermectin in preparing a promoter of the content of ciprofloxacin hydrochloride in Caco2 cells incubated with microplastics.